Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy

Successful Treatment of Early Relapsed High-Risk AML After Allogeneic Hematopoietic Stem Cell Transplantation With Biomodulatory Therapy

Early relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an often unsuccessful therapeutic challenge. Since treatment options are few and efficacy is low, new approaches such as de novo allo-HSCT, targeted therapies and biomodulatory drugs...

Full description

Bibliographic Details
Main Authors: Anna-Sophia Kattner, Ernst Holler, Wolfgang Herr, Albrecht Reichle, Daniel Wolff, Daniel Heudobler
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-04-01
Series:Frontiers in Oncology
Subjects:
acute myeloid leukemia
relapse
allogeneic stem cell transplantation
biomodulatory treatment
anakoinosis
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00443/full

Similar Items

Similar Items